

## **Technology Advisory Interests Register**

Topic: Seladelpar for previously treated primary biliary cholangitis [ID6429]

**Publication Date: TBC** 

| Name                       | Role with NICE             | Type of interest   | Description of interest   | Interest<br>declared     | Comments  |
|----------------------------|----------------------------|--------------------|---|--------------------------|---|
| Matt Bradley               | TAC<br>Committee<br>Member | Direct - financial | I hold shares in GSK who have recently published positive Phase 3 data for a potential new medicine called Linerixibat for the treatment of cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC).              | 18/06/2025               | It was agreed that Matt's declaration would prevent them from participating in discussions on this appraisal. |
| Sital Shah                 | Expert                     | Direct - financial | Gilead – Speaker fees and educational grants, IPSEN - Speaker fees and educational grants.  | 03/02/2025               | It was agreed that Sital's declaration would not prevent them from providing expert advice to the committee.  |
| Dr Palak Trivedi           | Expert                     | Direct - financial | I am director of PJT Medical Ltd., which provides advisory and consultancy services to the private sector with regards drug and device development (predominantly gastrointestinal and liver disease). This is not exclusive to Gilead. | 11/12/2024<br>10/09/2025 | It was agreed that Palak's declaration would not prevent them from providing expert advice to the committee.  |
| Robert Mitchell -<br>Thain | Expert                     | Direct - financial | The PBC Foundation has received funding from Gilead, but not within the last 12 months.   | 09/07/2025               | It was agreed that Robert's declaration would not prevent them from   |



| Name | Role with NICE | Type of interest   | Description of interest   | Interest<br>declared | Comments                                  |
|------|----------------|--------------------|---|----------------------|---|
|      |                | Direct - Financial | Funding to nominating organisation PBC Foundation from Gilead 2024 financials within last 12 months  £20,000 - Bronze corporate sponsorship £4,000 - Argentina Conference £40,000 - Translation website £35,000 - Summit 2025 £5,000 - Online Drs Pulse module £300 - PFIS patient narrative consulting fees (completed) £700 - EASL PAG meeting consulting fees £150000 - Patient Conference sponsorship (committed in December 2024, paid in 2025) £800 - Doctors.net modules £1000 - PBC medical education meeting | 10/09/2025           | providing expert advice to the committee. |